Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Firefly Neuroscience, Inc. (AIFF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: AIFF (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.17% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.84M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.86 - 17.20 | Updated Date 06/16/2025 |
52 Weeks Range 1.86 - 17.20 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4802.33% |
Management Effectiveness
Return on Assets (TTM) -86.34% | Return on Equity (TTM) -860.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37724522 | Price to Sales(TTM) 279.43 |
Enterprise Value 37724522 | Price to Sales(TTM) 279.43 | ||
Enterprise Value to Revenue 271.4 | Enterprise Value to EBITDA - | Shares Outstanding 12861100 | Shares Floating 8202680 |
Shares Outstanding 12861100 | Shares Floating 8202680 | ||
Percent Insiders 40.48 | Percent Institutions 9.56 |
Upturn AI SWOT
Firefly Neuroscience, Inc.
Company Overview
History and Background
Firefly Neuroscience, Inc., founded in 2008, is a neurotechnology company focused on developing advanced brain health assessment tools. It evolved from research on quantitative electroencephalography (qEEG) and event-related potentials (ERPs) to create a clinical decision support system.
Core Business Areas
- Clinical Decision Support: Development and commercialization of a platform that integrates EEG data with machine learning to provide insights for diagnosing and treating cognitive and neurological disorders.
- Pharmaceutical Services: Partnerships with pharmaceutical companies to use Firefly's technology for clinical trials and drug development, specifically for measuring drug efficacy.
- Research: Conducts research to further refine its technology and expand its applications in various fields of neuroscience and mental health.
Leadership and Structure
The company's leadership team includes a CEO, CFO, and Chief Medical Officer, with a board of directors overseeing the company's strategic direction. The organizational structure is designed to support research, product development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- Firefly Brain Performance Index (BPI): A quantitative EEG (qEEG)-based tool designed to aid clinicians in evaluating brain function and diagnosing cognitive impairments. Market share is still emerging as the company is relatively new to commercialization; primary competitors include companies offering traditional EEG analysis, neuropsychological testing, and brain imaging solutions. Revenue data is limited due to its early stage. Competitors: ANT Neuro, Brain Products GmbH, Compumedics Neuroscan.
Market Dynamics
Industry Overview
The neurotechnology industry is experiencing significant growth, driven by increasing awareness of brain health and advancements in neuroimaging and data analytics. The market is characterized by a mix of established players and innovative startups, with a focus on personalized medicine and digital health solutions.
Positioning
Firefly Neuroscience, Inc. is positioned as an innovator in qEEG-based clinical decision support. Its competitive advantage lies in its proprietary algorithms and machine learning models that extract meaningful insights from EEG data.
Total Addressable Market (TAM)
The global neurotechnology market is estimated to reach hundreds of billions of dollars. Firefly Neuroscience, Inc. is positioned to capture a portion of this TAM by providing advanced solutions for brain health assessment and diagnostics.
Upturn SWOT Analysis
Strengths
- Proprietary qEEG-based technology
- Potential for personalized medicine applications
- Partnerships with pharmaceutical companies
- Experienced leadership team
Weaknesses
- Limited commercial traction
- Dependence on regulatory approvals
- Relatively small size compared to competitors
- Limited brand awareness
Opportunities
- Expanding applications in mental health and cognitive disorders
- Increasing demand for objective brain health assessments
- Partnerships with healthcare providers
- Geographic expansion
Threats
- Competition from established neurotechnology companies
- Regulatory hurdles
- Reimbursement challenges
- Technological obsolescence
Competitors and Market Share
Key Competitors
- ANTU
- Philips (PHG)
- Natus Medical Incorporated (NTUS)
Competitive Landscape
Firefly Neuroscience, Inc. offers a unique platform for brain health assessment using qEEG, which could give it a competitive advantage. However, it faces competition from larger, more established companies with broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on product development and clinical validation.
Future Projections: Future growth is projected to be driven by increasing adoption of its technology in clinical practice and pharmaceutical research. Analyst estimates are not broadly available due to limited coverage.
Recent Initiatives: Recent initiatives include expanding its clinical network, securing regulatory approvals, and forging partnerships with key opinion leaders in the field.
Summary
Firefly Neuroscience is an early-stage neurotechnology company with a promising qEEG-based platform for brain health assessment. While its technology holds potential, the company faces challenges related to commercial traction, regulatory approvals, and competition from larger players. Partnerships with pharmaceutical companies and expansion into new clinical areas could drive future growth. Careful monitoring of regulatory changes and market dynamics is essential for the company's success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Limited Public Financial Data
- Market Research Reports
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice. Market data and estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Firefly Neuroscience, Inc.
Exchange NASDAQ | Headquaters Kenmore, NY, United States | ||
IPO Launch date 2011-02-23 | CEO & Director Mr. Greg Lipschitz | ||
Sector Technology | Industry Software - Application | Full time employees 13 | Website https://fireflyneuro.com |
Full time employees 13 | Website https://fireflyneuro.com | ||
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.